Insights - This afternoon, the FDA approved an expanded label for Vascepa to include patients who have: established cardiovascular disease (ie. heart attack, chest pain) or diabetes … Continue Reading
Premium: Read NowInsights - La Jolla Pharma (LJPC) is a beat up contrarian play that has dropped roughly 70% since September. Why? Because: (1) Commercial launch of Giapreza has … Continue Reading
Premium: Read NowInsights - Affimed (AFMD) had a call discussing Q3 results this morning. We were looking to see if anything had materially changed, especially after Affimed announced a … Continue Reading
Premium: Read NowInsights - The FDA’s ADCOM panel unanimously backed Amarin with a 16-0 vote, supporting expanded label. The FDA’s final decision to approve label expansion is still undetermined, … Continue Reading
Premium: Read NowInsights - This morning, the FDA released briefing documents that will be used as guidance by the panel members of the advisory committee (ADCOM) for Amarin’s Vascepa this Thursday. The package … Continue Reading
Read NowInsights - Spring Bank announced disappointing data from their combination trial with Gilead. At 12 weeks, 7/30 (23%) patients were responders with >0.5 log reduction at the 50mg inarigivir … Continue Reading
Premium: Read NowInsights - Adverum (ADVM) released additional Phase 1 data this past weekend at the American Academy of Ophthalmology (AAO) Meeting in San Francisco. The company gave an update at a median … Continue Reading
Member: Read Now
